Our projects showcase how we apply quantitative methods and strategic thinking to real-world challenges, supporting decision-making across different stages of product development.
Early market sizing and revenue forecasts for a Phase 1 asset in women’s health
February 2026 – Ongoing
For a clinical-stage biotech company, we developed early market sizing and revenue forecasts for a Phase 1 asset targeting a common disorder in the female population. The work included segmenting the broader patient population, identifying commercially relevant subgroups, and building alternative patient funnels to reflect different market scenarios. We assessed competitive dynamics, price potential, and expected uptake to estimate revenue potential and identify the main drivers of commercial value.
Operating cost estimates for a clinical-stage biotech
February 2026 – Ongoing
For a clinical-stage biotech company preparing to initiate Phase 3 for its lead candidate, we developed cost estimates for building the commercial infrastructure, launching the product, and transitioning to a fully integrated biotech company. The analysis combined bottom-up cost modelling with benchmarking against comparable biotech launches to provide a realistic view of the investment required before, during, and after launch.
Revenue forecasting for two clinical-stage assets in rare blood disorders
October 2025 – March 2026
For a clinical-stage biotech company, we developed revenue forecasts for two lead assets in development as prophylactic treatments for three different rare blood disorders. The work involved building detailed patient-based forecasting models, testing alternative commercial assumptions, and quantifying uncertainty around key drivers. We also developed a structured framework to ensure forecasts could be updated consistently as new data become available.